Last mentioned: Mar 17, 2026
Implementation
New list prices and Medicare negotiated rates take effect for Ozempic and Wegovy.
Negotiated Prices Effective
New Medicare-negotiated prices for selected drugs are scheduled to take effect.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reductions for semaglutide products.
Price Cut Announcement
Novo Nordisk officially announces 50% list price reduction for 2027.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on high U.S. prices.
Senate Hearing
Novo Nordisk CEO Lars Fruergaard Jørgensen testifies before the Senate HELP Committee on drug pricing.
CMS Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
Medicare Selection
Ozempic selected as one of the first 10 drugs for Medicare price negotiation.
Novo Nordisk has announced a landmark decision to reduce the list prices of its blockbuster GLP-1 medications, Ozempic and Wegovy, by up to 50%. The move follows intense regulatory scrutiny and the implementation of Medicare price negotiations under the Inflation Reduction Act.
Novo Nordisk has announced a major strategic shift by pledging to reduce the list prices of its blockbuster GLP-1 drugs, Ozempic and Wegovy, by up to 50% starting in 2027. This move follows intense regulatory pressure and the inclusion of Ozempic in Medicare's price negotiation program.
This page surfaces every story mentioning Wegovy across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Wegovy was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |